Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artelo Biosciences, Inc. (NASDAQ: ARTL) SEC filings page on Stock Titan provides structured access to the company’s U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on lipid-signaling pathways and the endocannabinoid system, Artelo uses its SEC filings to report on clinical development, capital formation, governance changes, and listing status.
Here you can review Form 10-K annual reports and Form 10-Q quarterly reports (when filed) for detailed discussions of Artelo’s pipeline, including programs such as ART27.13 for cancer anorexia-cachexia syndrome, ART26.12 as a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, and ART12.11, its CBD-TMP cocrystal composition. These reports typically describe risk factors, research and development priorities, intellectual property, and liquidity and capital resources.
Form 8-K current reports are particularly important for ARTL, as they capture material events such as underwritten public offerings, private placements of convertible notes and warrants, cooperation agreements with shareholders, amendments to bylaws and articles of incorporation, executive appointments, and Nasdaq listing notifications. For example, an 8-K dated November 25, 2025 discloses a Nasdaq delist determination letter related to stockholders’ equity requirements and the company’s intention to appeal.
Investors can also use this page to access registration statements such as Form S-1 and Form S-3, which describe the terms of securities offerings, resale registrations for warrants and convertible notes, and related risk disclosures. Where available, Section 16 filings (Forms 3, 4, and 5) provide insight into insider ownership and transactions involving directors and officers.
Stock Titan’s platform enhances these filings with AI-generated summaries that highlight key terms, financial and capital structure changes, and program-related disclosures, helping users quickly understand how each document relates to Artelo’s clinical pipeline, governance, and Nasdaq listing status.
Artelo Biosciences reports terminating a previously agreed private placement and a related consulting arrangement. The company and accredited investors signed a Termination and Mutual Release Agreement on August 19, 2025 that voids from inception a Securities Purchase Agreement covering 593,252 common shares and warrants to purchase up to 2,126,809 shares, along with all related documents. Artelo must return any purchase price previously received and has paid $50,000 to investors’ counsel for legal fees, with no termination penalties for either side.
Separately, Artelo and ABK Labs, Inc. agreed to terminate a Consulting Agreement and a Consultant Warrant for up to 55,000 shares, effective August 16, 2025. The consultant irrevocably forfeited all vesting and exercise rights under the warrant, and both sides exchanged broad mutual releases of claims, with no cash consideration paid in connection with this termination.
Artelo Biosciences filed a Form D reporting a Regulation D exempt offering under Rule 506(b) for a total offering of $9,475,000, all of which has been sold with $0 remaining. The filing identifies the securities as equity, options/warrants and securities to be acquired upon exercise, and lists the first sale date as 2025-08-05. The issuer indicates the offering will not last more than one year.
The notice records 18 investors, states $0 in sales commissions and finders' fees, and reports
Artelo Biosciences reported a quarterly net loss of $3.221 million and a six-month net loss of $5.593 million, while holding $2.066 million in cash and cash equivalents as of June 30, 2025. Current liabilities increased to $5.712 million, producing a working capital deficit of $3.479 million, and management discloses substantial doubt about the Company’s ability to continue as a going concern within one year.
The company completed financings including $900,000 of convertible notes bearing 12% interest (net carrying value $791,000), a June private placement that generated $1.425 million gross ($1.079 million net), an ATM sales agreement for up to $6.5 million, and an expected August PIPE targeting approximately $9.475 million. The Company adopted a Digital Asset Treasury strategy to acquire Solana (SOL); under ASU 2023-08 SOL fair-value changes will flow through net income.
Artelo Biosciences (ARTL) entered into a private placement on 1 Aug 2025, selling 593,252 common shares at $10.20 and 313,435 prefunded warrants at $0.001, each paired with one three-year warrant at $10.20 and one at $50.00. Unit prices of $10.45 (shares) or $10.449 (prefunded) will deliver $9.475 million in gross cash; full cash exercise of the 1.81 million bundled warrants could raise an additional $64.1 million.
Proceeds from the share sale will be used immediately to purchase the cryptocurrency Solana (SOL). Any warrant cash will first fund 12 months of operating requirements; remaining amounts may also be deployed into SOL. The shift establishes a new cryptocurrency treasury strategy and triggers extensive risk disclosures covering SOL price volatility, regulatory uncertainty, Nasdaq listing compliance, Investment Company Act exposure and potential CAMT liabilities.
The offering, exempt under Reg D, is expected to close 5 Aug 2025, with a resale registration due within 15 days. In a separate 7.01 disclosure, the company announced favourable UK MHRA guidance for a first-in-human Phase 1 trial of anxiety-depression candidate ART12.11.
Artelo Biosciences, Inc. (ARTL) filed a new Form D on 9 Jul 2025 that covers a $1.425 million private placement conducted under Regulation D Rule 506(b).
- Total offering & amount sold: $1,425,000; amount remaining: $0, indicating the raise is already fully subscribed.
- Date of first sale: 26 Jun 2025; the company does not expect the offering to last longer than one year.
- Securities offered: common equity, options/warrants, and the shares issuable upon exercise of those instruments.
- Investors: 8 accredited investors participated; no non-accredited investors and no minimum investment requirement were specified.
- Costs: No sales commissions or finders’ fees were paid, and none of the proceeds are earmarked for payments to directors, officers, or promoters.
- Industry & issuer details: Nevada-incorporated biotechnology company; revenue size not disclosed.
The notice signals completion of a small but cost-efficient capital raise that adds liquidity while increasing potential share count through equity-linked securities.